T

    Tiziana Life Sciences Ltd (TLSA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.99
    -0.02 (-2.18%)

    Market Cap: $125.73M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    44%(4/9)
    Avg Surprise
    -80.66%
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    Reported Aug 7
    		$N/AN/AN/ABeat-
    Sep 25
    Reported Oct 13
    		$-0.05$0.00N/AMiss+72.3%
    Jun 25
    Reported Jul 8
    		$-0.10$-0.07-35.38%Miss+55.5%
    Mar 25
    Reported May 20
    		$-0.07N/AN/ABeat-16.7%
    Sep 24
    Reported Oct 18
    		$-0.05$0.00N/AMiss+16.7%
    Jun 24
    Reported Jun 30
    		$-0.18N/AN/ABeat-
    Dec 22
    Reported Apr 26
    		$-0.22N/AN/ABeat-170.5%
    Sep 22
    Reported Dec 27
    		$-0.06$0.00N/AMiss-6.2%
    Mar 22
    Reported May 22
    		$-0.06$-0.06+0.00%Beat-3.8%
    Sep 21
    Reported Dec 1
    		$0.00$0.00N/ABeat+100.0%
    Jun 21
    Reported Sep 24
    		$-0.08$0.00N/AMiss-102.0%
    Mar 21
    Reported May 17
    		$-0.06$-0.04-42.68%Miss-42.7%
    Dec 20
    Reported Mar 31
    		$-0.06$0.00N/AMiss-254.6%
    Sep 20
    Reported Dec 2
    		$-0.04$-0.04+0.00%Beat+71.7%
    Jun 20
    Reported Sep 30
    		$-0.04$-0.01-296.00%Miss+67.0%
    Mar 20
    Reported Jun 17
    		$-0.04N/A+84.16%Beat-17.9%
    Dec 19
    Reported Mar 31
    		$-0.02$0.00N/AMiss+5.8%
    Sep 19
    Reported Nov 27
    		$-0.14$-0.14+0.00%Beat-1150.0%
    Jun 19
    Reported Sep 30
    		$-0.12$-0.04-200.00%Miss-20.1%
    Mar 19
    Reported Apr 4
    		$-0.03$-0.01-236.00%Miss-66.3%
    Dec 18
    Reported Mar 31
    		$-0.02$0.00N/AMiss+19.5%
    Sep 18
    Reported Nov 21
    		$-0.01$0.00N/AMiss+78.7%
    Jun 18
    Reported Sep 24
    		$-0.10$0.00N/AMiss+5.5%
    Mar 18
    Reported Jun 30
    		$-0.02$0.00N/AMiss+20.8%
    Dec 17
    Reported Mar 31
    		$-0.02$0.00N/AMiss+15.7%
    Sep 17
    Reported Nov 29
    		$-0.05$0.00N/AMiss-58.3%
    Jun 17
    Reported Sep 29
    		$-0.11$0.00N/AMiss-
    Mar 17
    Reported May 31
    		$-0.03$0.00N/AMiss-
    Dec 16
    Reported Mar 31
    		$-0.03$0.00N/AMiss-
    Sep 16
    Reported Dec 31
    		$-0.03$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-3.71EV/EBITDA-5.98x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-924.00%ROIC-14217.69%
    Financial Health
    Debt/Equity4.27xInterest Coverage-684.89x
    Current Ratio0.76xQuick Ratio0.76x
    Trading Statistics
    Beta0.46Avg Volume1.16M
    52-Week High$2.3552-Week Low$0.87

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.09
    SMA 20$1.06
    SMA 50$1.09
    SMA 200$1.35
    EMA 10$1.06
    EMA 20$1.06
    EMA 50$1.10
    EMA 200$1.30

    MACD

    Line: -0.00Signal: 0.00Hist: -0.00

    ADX

    ADX: 17.5+DI: 17.7-DI: 18.4

    Aroon & PSAR

    Aroon Up80.0
    Aroon Down20.0
    PSAR$1.25

    Bollinger Bands

    Upper Band$1.19
    Lower Band$0.93
    %B Position2479%(Upper)
    Band Width0.24

    RSI (14-Day)

    Neutral
    41.2

    Momentum Oscillators

    Stoch %K27.9
    Stoch %D38.7
    Williams %R-84.4
    ROC (10d)-14.1%
    Momentum-0.16
    CCI (20d)-72.2
    MFI (14d)38.3

    Volatility Measures

    ATR (14d)$0.10(10.3%)
    StdDev (20d)0.07
    Hist Vol57.1%(High)

    Volume Flow

    VWAP$1.00
    OBV7.7M
    AD Line4.1M
    CMF (20d)-0.067

    Volume Metrics

    Avg Vol (20d)1.1M
    Vol Ratio0.4x(Low)
    VWMA (20d)$1.06

    Pivot Points

    R3$1.18
    R2$1.14
    R1$1.07
    Pivot Point$1.04
    S1$0.97
    S2$0.93
    S3$0.87

    Advanced Oscillators

    TSI-1.29
    Ultimate Osc33.0
    KST26.30

    Financial Data

    QuarterMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Total RevenueN/A$0N/AN/AN/A$0N/AN/AN/AN/AN/AN/A
    Cost of Revenue$146,000$146,000$88,000$88,000$61,000$61,000$126,000$126,000$41,000$41,000$-51,919$-41,000
    Gross Profit$-146,000$-146,000$-88,000$-88,000$-61,000$-61,000$-126,000$-126,000$-41,000$-41,000$-55,000$41,000
    Operating Expenses$12.18M$12.18M$8.87M$8.87M$9.13M$9.13M$12.76M$12.76M$6.19M$6.19M$14.93M$11.79M
    R&D$7.04M$7.04M$3.24M$3.24M$2.65M$2.65M$5.15M$5.15M$4.83M$4.83M$4.16M$3.29M
    SG&A$0$5.15M$0$0$0$6.48M$0$0$0$0$0$0
    Operating Income$-12,328,000$-12,328,000$-8,956,000$-8,956,000$-9,193,000$-9,193,000$-12,886,000$-12,886,000$-6,233,000$-6,233,000$-14,880,585$-11,751,000
    Interest Income$0$14,000$0$0$0$702,000$0$0$0$0$0$0
    Interest Expense$18,000$18,000$0$0$6,000$6,000$3.07M$3.07M$5,000$5,000$6,331$5,000
    Income Before Tax$-12,799,000$-12,799,000$-5,632,000$-5,632,000$-8,766,000$-8,766,000$-15,960,000$-15,960,000$-8,625,000$-8,625,000$-10,911,922$-8,617,000
    Income Tax Expense$0$0$0$0$-1,557,000$-1,557,000$-6,652,000$-6,652,000$449,000$449,000$0$0
    Net Income$-12,799,000$-12,799,000$-5,632,000$-5,632,000$-7,209,000$-7,209,000$-9,308,000$-9,308,000$-9,074,000$-9,074,000$-10,911,922$-8,617,000
    EBITDA$-12,182,000$-12,182,000$-5,544,000$-5,544,000$-8,699,000$-8,699,000$-15,834,000$-15,834,000$-8,579,000$-8,579,000$-10,835,943$-8,557,000
    EBIT$-12,328,000$-12,328,000$-5,632,000$-5,632,000$-8,760,000$-8,760,000$-15,960,000$-15,960,000$-8,620,000$-8,620,000$-10,905,590$-8,612,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TLSA

    News

    Market movers: Strategy, Bitmine, Tiziana Life Sciences...

    This article highlights key market movers, including Expion Energy which saw a significant stock jump after closing an initial $9 million private placement for oil and gas exploration assets. Bitmine Immersion Technologies reported $14.9 billion in crypto holdings, while MicroStrategy raised $2.01 billion through an equity offering without selling its bitcoin. Tiziana Life Sciences announced an upcoming presentation on its Phase 2a clinical trial for intranasal foralumab at ALS Nexus 2026.

    Proactive financial news•8/24/26•
    Neutral

    Market movers: Strategy, Bitmine, Tiziana Life Sciences...

    Expion Energy closed the initial tranche of a $9 million private placement to fund oil and gas exploration assets, causing shares to jump. Bitmine Immersion Technologies reported significant crypto holdings, including over 5 million staked ETH and 210 Bitcoin, leading to a rise in its shares. MicroStrategy Incorporated completed a $2.01 billion equity offering to strengthen liquid reserves without selling its bitcoin holdings, and Tiziana Life Sciences Ltd is presenting Phase 2a clinical trial data for intranasal foralumab at ALS Nexus 2026.

    Proactive financial news•8/24/26•
    Somewhat-Bullish

    Tiziana (NASDAQ: TLSA) highlights intranasal ALS trial and MS data

    Tiziana Life Sciences (NASDAQ: TLSA) announced a poster presentation at ALS Nexus 2026 detailing its Phase 2a BANYAN clinical trial of intranasal foralumab for amyotrophic lateral sclerosis (ALS). The trial focuses on the role of regulatory T cells in ALS biology and positions intranasal foralumab as a non-invasive immunomodulatory approach. The company also reported positive outcomes from an open-label Expanded Access program, where 14 patients with non-active secondary progressive multiple sclerosis showed improvement or stability within six months after being dosed with intranasal foralumab.

    Stock Titan•8/24/26•
    Somewhat-Bullish

    Tiziana Life Sciences Ltd.

    Tiziana Life Sciences announced a poster presentation on its Phase 2a BANYAN clinical trial of intranasal foralumab for ALS at ALS Nexus 2026. The trial, part of the Healey ALS MyMatch program, evaluates the safety, biomarkers, and clinical effects of foralumab, a fully human anti-CD3 monoclonal antibody, in people with ALS. Foralumab aims to activate regulatory T cells to suppress neuroinflammation and rebalance microglial activity, offering a potential non-invasive approach to slow ALS progression.

    Via Ritzau•8/24/26•
    Bullish

    Tiziana Life Sciences to present Phase 2a BANYAN trial data at ALS Nexus 2026

    Tiziana Life Sciences (NASDAQ:TLSA) will present data from its Phase 2a BANYAN clinical trial for intranasal foralumab at ALS Nexus 2026. The presentation will detail the study's design, preclinical data, and its focus on assessing safety, immune modulation, and neuroinflammation biomarkers in ALS patients. The trial is supported by a grant from the ALS Association and other foundations.

    Proactive financial news•8/24/26•
    Bullish

    Frequently Asked Questions About TLSA

    Does TLSA pay dividends?
    Tiziana Life Sciences Ltd (TLSA) does not currently pay a regular dividend.
    What is TLSA's market cap?
    Tiziana Life Sciences Ltd (TLSA) has a market capitalization of $125.73M with a current stock price of $0.99.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In